Demetrios Braddock, MD, PhD

Demetrios Braddock was born in Tennessee, educated at the University of Chicago, trained at the NIH in Anatomic Pathology and Biophysical Chemistry, and came to Yale in 2004. He practices Hematopathology and a heads a laboratory whose focus is on rare diseases of children and the design and engineering of novel biologics to modulate disease outcome. Dr. Braddock's work on a rare disease of lethal vascular calcifications in infants called 'Generalized Arterial Calcification of Infancy' (GACI) led to the design and validation of an enzyme biologic which has successfully moved 'bench to bedside' into the clinic through the founding of Inozyme Pharma. Successful phase 1-2 clinical trial data in ENPP1 and ABCC6 deficiency was reported in Feb. 2023 (ClinicalTrials.gov: NCT04686175 & NCT05030831), and phase 3 studies are currently underway. Continued work on ENPP1 function includes the association of ENPP1 halploinsuffiency with early onset osteoporosis, the therapeutic effects of ENPP1 biologics on 'Paradoxical Mineralization' in prevalent medical diseases such as aging and chronic kidney disease, and the molecular mechanism by which an ENPP1 variant induces metabolic syndrome and obesity in children.